Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 846

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 846
---
 to be approved for listing on Nasdaq and accepted for clearance by the DTC, subject to official notice of issuance and meet the listing requirements for Nasdaq, prior to the Closing Date. Section 8.7 Notice of Developments . During the Interim Period, each of the Company, Merger Sub and MultiplAI shall promptly (and in any event prior to the Closing) notify SPAC in writing, upon the Company, any of the Company’s Subsidiaries, MultiplAI or any of MultiplAI’s Subsidiaries, as applicable, becoming aware (awareness of the Company or any of its Subsidiaries being determined with reference to the knowledge of the Company and awareness of the Annex A-71 MultiplAI or any of its Subsidiaries being determined with reference to the knowledge of MultiplAI) of: (a) the occurrence or non-occurrence of any event the occurrence or non-occurrence of which has caused or is reasonably likely to cause a breach of any of the representations and warranties, covenants or obligations of any party to the Transaction Documents or any condition to the obligations of any party to effect the Transactions not to be satisfied, including, but not limited to, the conditions set forth in Article XI , (b) the occurrence or non-occurrence of any event the occurrence or non-occurrence of which has caused or is reasonably likely to cause a breach of any of the representations and warranties, covenants or obligations of any party to the MultiplAI Share Purchase Agreement or any condition to the obligations of any party to the MultiplAI Share Purchase Agreement to effect the transactions contemplated thereby not to be satisfied, including, but not limited to, the conditions set forth in Section 4 of the MultiplAI Share Purchase Agreement, or (c) any notice or other communication from any Governmental Authority which is reasonably likely, individually or in the aggregate, to have a Company Material Adverse Effect or a MultiplAI Material Adverse Effect. The delivery of any notice pursuant to this Section 8.7 shall not cure any breach of any representation or warranty requiring disclosure of such matter or any breach of any covenant, condition or agreement contained in this Agreement or any other Transaction Document or otherwise limit or affect the rights of, or the remedies available to, SPAC or any other party to this Agreement or the Transaction Documents. Section 8.8 No Trading . Each of the Company, Merger Sub and MultiplAI acknowledges and agrees that it